Drug Trial Radar · NCT05577312
Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia
Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
39
Actual
Start
Nov 2, 2022
Primary completion
Oct 20, 2026
Study completion Jul 10, 2027
Sponsor
- Lead sponsor
- Bioray LaboratoriesIndustry
- Sponsor type
- Industry
- Collaborators
- First Affiliated Hospital of Guangxi Medical University; Xiangya Hospital of Central South University; Chinese Academy of Medical Sciences; Nanfang Hospital, Southern Medical University; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army; Shenzhen Children's Hospital
- First posted
- Oct 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a non-randomized, open label, multi-site, single-dose, phase 1/2 study in subjects with Transfusion-Dependent β-Thalassemia (TDT). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (BRL-101)
Conditions
- Beta-Thalassemia
Interventions
BRL-101Drug
CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A enhancer site
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of stem cell engrafted subjectsTime frame: Within 42 Days After BRL-101 Infusion
- Time to neutrophil engraftmentTime frame: Up to 12 Months After BRL-101 Infusion
- Frequency, severity, and relationship to BRL-101 of adverse events over 12 months following BRL-101 infusionTime frame: Up to 12 Months After BRL-101 Infusion
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Universit
Guanzhou, Guangdong, China
Shenzhen Children 's Hospital
Shenzhen, Guangdong, China
No. 923 Hospital of Joint Support Force of Chinese People 's Liberation Army Hospital
Nanning, Guangxi, China
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
Xiangya Hospital of Central South University
Changsha, Hunan, China
Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.